Fiona Chan

Fiona Chan

Auto-generated profile, based on publicly available information

Fiona Chan

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2017 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
ANAnjali Nagpal
Anjali Nagpal
FCFong Chan Choy
Fong Chan Choy
SHStuart Howell
Stuart Howell
SHSusan Hillier
Susan Hillier
FCFiona Chan
Fiona Chan
SKSimon A. Koblar
Simon A. Koblar
Stem cells have demonstrated encouraging potential as reparative therapy for patients suffering from post-stroke disability. Reperfusion interventions in the acute phase of stroke have shown significant benefit but are limited by a narrow window of opportunity in which they are beneficial. Thereafter, rehabilitation is the only intervention available. The current review summarises the current evidence for use of stem cell therapies in stroke from early-phase clinical trials. The safety and feasibility of administering different types of stem cell therapies in stroke seem to be reasonably proven. However, the effectiveness needs still to be established through bigger clinical trials with more pragmatic clinical trial designs that address the challenges raised by the heterogeneous nature of stroke per se, as well those due to unique characteristics of stem cells as therapeutic agents.

10 April 2019 in BMC Rheumatology
Verified
Journal Article
Open access
PDF file
FCFiona Li Ying Chan
Fiona Li Ying Chan
SLSusan Lester
Susan Lester
SWSamuel Lawrence Whittle
Samuel Lawrence Whittle
CHCatherine Louise Hill
Catherine Louise Hill
To compare the utility of ESR, CRP and platelets for the diagnosis of GCA. A clinical diagnosis of GCA was determined by case-note review of 270 individuals (68% female, mean age 72 years) referred to a central pathology service for a temporal artery biopsy between 2011 and 2014. The highest levels of ESR, CRP and platelets (within 2 weeks of diagnosis) were documented. Evaluation of ESR, CRP and platelets for the diagnosis of GCA were compared using Receiver Operating Characteristic Area Under the Curve (ROC-AUC), and sensitivity/specificity at optimum cut-off values. GCA was clinically diagnosed in 139 (67%) patients, with 81 TAB positive. The AUC estimates for ESR, CRP and platelets were comparable (0.65 vs 0.72 vs 0.72, p = 0.08). The estimated optimal cut-off levels were confirmed at 50 mm/hour for ESR, and determined as 20 mg/L for CRP and 300 × 109/L for platelets. Sensitivity estimates for these three tests were comparable (p = 0.45) and ranged between 66% for ESR and 71% for platelets. Specificity estimates were also comparable (p = 0.11) and ranged between 57% for ESR and 68% for CRP. There was only moderate agreement between the three positive tests (agreement 67%, kappa: 0.34), and when considered collectively, CRP and platelet positive tests were independent predictors of GCA (p < 0.001), but the ESR was not (p = 0.76). ESR, CRP and platelets are moderate, equivalent diagnostic tests for GCA, but may yield disparate results in individual patients. A combination of CRP and platelet tests may provide the best diagnostic utility for GCA.

21 November 2023 in Neurology
Verified
Journal Article
Open access
PDF file
SASally Abbott
Sally Abbott
FCFiona Chan
Fiona Chan
ATAbd A. Tahrani
Abd A. Tahrani
SWSui H Wong
Sui H Wong
FCFiona E.J. Campbell
Fiona E.J. Campbell
SMSusan P Mollan
Susan P Mollan
Background and Objectives Idiopathic intracranial hypertension (IIH) is associated with obesity, however there is a lack of clinical consensus on how to manage weight in IIH. The aim of this systematic review is to evaluate weight loss interventions in people with IIH to determine which intervention is superior in terms of weight loss, reduction in intracranial pressure, benefit to visual and headache outcomes, quality of life, and mental health. Methods A systematic review was carried out in accordance with PRISMA guidelines and registered with PROSPERO (CRD42023339569). MEDLINE and CINAHL were searched for relevant literature published from inception until 15th December 2022. Screening and quality appraisal was conducted by two independent reviewers. Recommendations were graded using Scottish Intercollegiate Guidelines Network (SIGN) methodology. Results A total of 17 studies were included. Bariatric surgery resulted in 27.2-27.8kg weight loss at 24 months (Level 1- to 1++). Lifestyle weight management interventions resulted in between 1.4 to 15.7kg weight loss (Level 2+ to 1++). Bariatric surgery resulted in the greatest mean reduction in ICP (-11.9cm H2O) at 24 months (Level 1++), followed by multi-component lifestyle intervention + acetazolamide (-11.2cm H2O) at 6 months (Level 1+), and then a very low energy diet intervention (-8.0cm H2O) at 3 months (Level 2++). The least ICP reduction was shown at 24 months after completing a 12-month multi-component lifestyle intervention (-3.5 cm H2O) (Level 1++). Reduction in body weight was shown to be highly correlated with reduction in ICP (Level 2++ to 1++). Discussion Bariatric surgery should be considered for women with IIH and a BMI ≥35kg/m2 since this had the most robust evidence for sustained weight management (Grade A). A multi-component lifestyle intervention (diet + physical activity + behaviour) had the most robust evidence for modest weight loss with a BMI <35kg/m2 (Grade B). Longer term outcomes for weight management interventions in people with IIH are required, to determine if there is a superior weight loss intervention for IIH.

31 August 2021 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
PSPedro Sánchez
Pedro Sánchez
FCFiona Chan
Fiona Chan
THTodd A. Hardy
Todd A. Hardy
Tumefactive demyelination (TD) can be a challenging scenario for clinicians due to difficulties distinguishing it from other conditions, such as neoplasm or infection; or with managing the conseque...

19 November 2018 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
FCFiona Chan
Fiona Chan
ASAndrew Swayne
Andrew Swayne
DGDavid Gillis
David Gillis
MWMichael Walsh
Michael Walsh
RHRobert D Henderson
Robert D Henderson
SBStefan Blum
Stefan Blum
We previously reported on our experience with low-dose RTX in the treatment of MG3 and now report our long-term experience from an enlarged cohort.

8 July 2018 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
FCFiona L. Y. Chan
Fiona L. Y. Chan
BKBrendan Kennedy
Brendan Kennedy
RNRenjy Nelson
Renjy Nelson